WEBULL
News
ASND
234.95
+4.42%
9.95
Ascendis Pharma Sets March 23 AGM to Approve 2025 Results, Board Changes and Buyback Mandate
TipRanks · 3h ago
Assessing Ascendis Pharma (ASND) Valuation After A Year Of Strong Returns And Premium P/S Multiple
Simply Wall St · 5h ago
Ascendis (ASND) Q4 2025 Earnings Call Transcript
The Motley Fool · 6h ago
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX)
TipRanks · 11h ago
Weekly Report: what happened at ASND last week (0216-0220)?
Weekly Report · 15h ago
Does Stronger 2025 Results And Narrowing Losses Reshape The Bull Case For Ascendis Pharma (ASND)?
Simply Wall St · 5d ago
Morgan Stanley Remains a Buy on Ascendis Pharma (ASND)
TipRanks · 6d ago
Weekly Report: what happened at ASND last week (0209-0213)?
Weekly Report · 02/16 10:02
Is Ascendis Pharma (ASND) Still Attractive After Its Strong Multi Year Share Price Run?
Simply Wall St · 02/15 18:26
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Cooling
Simply Wall St · 02/14 17:36
Barclays Sticks to Its Buy Rating for Ascendis Pharma (ASND)
TipRanks · 02/13 11:39
Ascendis Pharma NasdaqGS ASND Revenue Surge Keeps Losses In Focus And Tests Bullish Narratives
Simply Wall St · 02/13 00:50
Ascendis Pharma Earnings Call Highlights Growth Momentum
TipRanks · 02/13 00:26
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026
Benzinga · 02/12 17:44
Ascendis Pharma Price Target Raised to $262.00/Share From $246.00 by Oppenheimer
Dow Jones · 02/12 17:10
Ascendis Pharma Is Maintained at Outperform by Oppenheimer
Dow Jones · 02/12 17:10
Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $262
Benzinga · 02/12 17:01
Ascendis Pharma Price Target Raised to $273.00/Share From $240.00 by Wedbush
Dow Jones · 02/12 14:50
Ascendis Pharma Is Maintained at Outperform by Wedbush
Dow Jones · 02/12 14:50
Wedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $273
Benzinga · 02/12 14:41
More
Webull provides a variety of real-time ASND stock news. You can receive the latest news about Ascendis Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ASND
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).